Company
Mineralys Therapeutics
We are focused on improving outcomes for people managing hypertension, CKD and related diseases that are driven by dysregulated aldosterone.
Also known as Mineralys Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2019
- Legal name
- Mineralys Therapeutics, Inc.
- mineralystx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We are deeply focused on how to address cardio-renal-metabolic syndrome (CRMS) diseases.
Funding snapshot
- Total raised
- $118MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $118M2022-06-01
Funding rounds
- Round, 2022
- $118M2022-06-01, SEC form D sold, 23 investors
Products
- Other
- lorundrostat (MLS-101)
Loading relationship preview